• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail

cafead

Administrator
Staff member
  • cafead   Nov 06, 2024 at 08:02: PM
via Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal.

article source